E-viri
Recenzirano
Odprti dostop
-
Robak, Tadeusz; Huang, Huiqiang; Jin, Jie; Zhu, Jun; Liu, Ting; Samoilova, Olga; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii; Alexeeva, Julia; Pereira, Juliana; Drach, Johannes; Mayer, Jiri; Hong, Xiaonan; Okamoto, Rumiko; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco
New England journal of medicine/The New England journal of medicine, 03/2015, Letnik: 372, Številka: 10Journal Article
The substitution of bortezomib for vincristine in R-CHOP resulted in higher rates of complete response and nearly a doubling in progression-free survival among patients with advanced mantle-cell lymphoma not eligible for stem-cell transplantation. Mantle-cell lymphoma is an incurable, aggressive hematologic cancer with a poor prognosis (median survival, 4 to 5 years). 1 , 2 It comprises 5 to 6% of all non-Hodgkin's lymphomas, including approximately 5000 cases per year in the United States. 3 For previously untreated patients who are either ineligible or not considered for intensive chemotherapy and stem-cell transplantation, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is a standard of care 4 – 6 and produces complete response rates of up to 48%. However, progression-free survival is limited (median, 16.6 months). 7 The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma in . . .
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.